American Kratom Association to Brief Congress on FDA's 7-OH Action and Federal Consumer Protection Bill

Why it matters

With states pursuing conflicting kratom regulations and no federal framework in place, a June 3, 2026 Congressional briefing could help shape federal kratom policy affecting an estimated 20 million American users.

The big picture

Nearly a year after the FDA's July 2025 recommendation to schedule synthetic 7-OH, no federal legislation has followed. States are moving in contradictory directions — some banning all kratom, others only restricting synthetic derivatives. The proposed Federal Kratom Consumer Protection Act aims to create a unified regulatory framework that distinguishes natural kratom from synthetic concentrates.

Key findings

• The American Kratom Association will host a Congressional Briefing on June 3, 2026 at the Capitol Visitor Center in Washington D.C.
• Nearly a year has passed since the FDA's July 2025 recommendation to schedule synthetic 7-OH, yet no federal legislation has followed
• An estimated 20 million Americans use kratom, yet no federal safety or manufacturing framework governs the market
• The Federal Kratom Consumer Protection Act would close regulatory gaps and establish manufacturing and consumer protection standards
• The briefing will clarify the distinction between natural kratom and concentrated synthetic 7-OH, which presenters argue are pharmacologically distinct

What they say

"Kratom is used by an estimated 20 million Americans, yet no federal framework governs how it is manufactured and sold," according to the American Kratom Association, which is organizing the Congressional briefing.

Bottom line

A June 3, 2026 Congressional briefing by the American Kratom Association aims to push for a unified federal consumer protection framework for kratom amid conflicting state laws and stalled federal action.